Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abuse Potential of Soticlestat in Healthy Adult Recreational Drug Users
NCT05602818Phase 1Completed
- Sponsor
- Takeda
- Start
- Nov 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of soticlestat in epilepsy (5 arms), sponsored by Takeda. Primary endpoint: Maximum Effect of Drug Liking 'At This Moment' at 24 hours. Started Nov 2022; status: completed.
02
Drugs
soticlestat
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05602818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05602818.